Acute On Chronic Liver Failure Epidemiology, Insights and Market Analysis

Posted on
by

Acute On Chronic Liver Failure Epidemiology, Insights and Market Analysis

(Albany, US) DelveInsight has launched a new report on Acute on Chronic Liver Failure Epidemiology

DelveInsight’s ‘Acute On Chronic Liver Failure (ACLF) – Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical and forecasted Acute On Chronic Liver Failure (ACLF) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The term Acute-on-Chronic Liver Failure (ACLF) was first introduced in 1995 to describe a condition in which two “lesions” or “insults” act simultaneously on the liver, one of which is chronic and the other is acute. However, the universally accepted and used definition of ACLF is still lacking. Thus, several definitions have been developed by expert groups from the American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), and Asian-Pacific Association for the Study of the Liver (APASL). According to AASLD and EASL working group ACLF is, “Acute deterioration of pre-existing chronic liver disease usually related to a precipitating event and associated with increased mortality at 3-months due to multi-system organ failure”. On the other hand, the group of experts from APASL define the ACLF as, “Acute liver injury manifesting as jaundice (serum bilirubin ≥5 mg/dL) and coagulopathy (INR ≥1.5 or prothrombin activity of <40%), complicated within 4 weeks by ascites and/or encephalopathy in a patient previously diagnosed or undiagnosed chronic liver diseases.”

 

Click here for Free sample page:-  https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-epidemiology-forecast

 

Acute on Chronic Liver Failure Epidemiology

Organ failure is a major factor in the clinical course of ACLF. Moreover, the presence of hepatic encephalopathy (HE) within 4 weeks is part of the criteria for defining ACLF. It can be due to hepatotropic or non-hepatotropic agents/causes. Major etiologic agents responsible for precipitating ACLF are Hepatotropic viral infections, such as Hepatitis B virus, infection and super-infection with HEV, etc., and Non-hepatotropic insults, like surgery, trauma, and viral infections if producing direct hepatic insult could lead to ACLF.

 

Key facts of the report

  • As per Delveinsight estimates, total population of Acute-on-Chronic Liver Failure (ACLF) in 7 MM was found to be 60,521 in 2017.
  • According to Delveinsight estimates, Germany accounted for the maximum cases which were 17,100 in 2017.
  • Among the 7MM, the United States had the second highest population of ACLF with 12577 cases. On the other hand, Italy had the lowest population of 1721 cases in 2017
  • Japan accounted for 3720 cases Acute on chronic Liver Failure in 2017

 

Acute on Chronic Liver Failure Report Scope

  • The Acute On Chronic Liver Failure (ACLF) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Acute On Chronic Liver Failure (ACLF) Epidemiology Report and Model provide an overview of the risk factors and global trends of Acute On Chronic Liver Failure (ACLF) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Acute On Chronic Liver Failure (ACLF) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Acute On Chronic Liver Failure (ACLF)
  • The report provides the segmentation of the Acute On Chronic Liver Failure (ACLF) epidemiology

 

Download free sample page:-  https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-epidemiology-forecast

 

Table of content

1. Key Insights

2. Executive Summary of Acute On Chronic Liver Failure (ACLF)

3. Competitive Intelligence Analysis for Acute On Chronic Liver Failure (ACLF)

4. Acute On Chronic Liver Failure (ACLF): Market Overview at a Glance

5. Acute On Chronic Liver Failure (ACLF): Disease Background and Overview

6. Patient Journey

7. Acute On Chronic Liver Failure (ACLF) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Acute On Chronic Liver Failure (ACLF) Treatment

11. Marketed Products

12. Emerging Therapies

13. Acute On Chronic Liver Failure (ACLF): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Acute On Chronic Liver Failure (ACLF)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Why should you buy this report?

  • The Acute On Chronic Liver Failure (ACLF) Epidemiology report will allow the user to –
  • Develop business strategies by understanding the trends shaping and driving the global Acute On Chronic Liver Failure (ACLF) market
  • Quantify patient populations in the global Acute On Chronic Liver Failure (ACLF) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Acute On Chronic Liver Failure (ACLF) therapeutics in each of the markets covered
  • Understand the magnitude of Acute On Chronic Liver Failure (ACLF) population by its epidemiology
  • The Acute on Chronic Liver Failure (ACLF) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Related Reports

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/